

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELDA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jason Peterson
Date of last notice	14 January 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<ul style="list-style-type: none">i. Jason Peterson and Lisa Peterson <J&L Peterson S/F A/C> (Beneficiary)ii. Celtic Capital Pty Ltd <The Celtic Capital A/C> (Director/Shareholder)iii. Celtic Capital Pte Ltd <Investment 1 A/C> (Director/Shareholder)iv. Professional Payment Services Pty Ltd (Director/Shareholder)v. CPS Capital Group Pty Ltd ('CPS') (Director/Shareholder)vi. Wicklow Capital Pty Ltd <Tipperary A/C> (Director/Shareholder)vii. Sunset Capital Management Pty Ltd <Sunset Superfund> (Director/Shareholder)
Date of change	<ul style="list-style-type: none">1) 31 January 20192) 30 January 2019

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	i. 8,000,000 options (\$0.03125; 17/11/2021) ii. 11,200,000 ordinary shares iii. 5,800,000 ordinary shares iv. 538,230 ordinary shares v. 568,421 ordinary shares vi. 1,642,105 ordinary shares vii. 52,459,017 ordinary shares
Class	1) Ordinary shares 2) Unlisted options exercisable at \$0.03125 on or before 17/11/2021
Number acquired	2) 8,000,000
Number disposed	1) 568,421 2) 8,000,000
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	
No. of securities held after change	i. Nil ii. 11,200,000 ordinary shares iii. 5,800,000 ordinary shares iv. 538,230 ordinary shares v. Nil vi. 1,642,105 ordinary shares vii. 52,459,017 ordinary shares viii. 8,000,000 options (\$0.03125; 17/11/2021)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1) Distribution to CPS shareholders as part of CPS's Dividend policy. 2) Internal restructure. No ultimate change in Director interest.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.